Empagliflozin improves cardiovascular and renal outcomes in patients with preserved ejection fraction irrespective of age: insights from the EMPEROR-Preserved trial

Michael Boehm; J. Butler; G. Filippatos; J. P. Ferreira; S. J. Pocock; A. Abdin; F. Mahfoud; M. Brueckmann; N. D. Gollop; T. Iwata; P. Ponikowski; C. Wanner; F. Zannad; M. Packer; S. D. Anker

doi:10.1002/ejhf.2569

Empagliflozin improves cardiovascular and renal outcomes in patients with preserved ejection fraction irrespective of age: insights from the EMPEROR-Preserved trial

Michael Boehm, J. Butler, G. Filippatos, J. P. Ferreira, S. J. Pocock, A. Abdin, F. Mahfoud, M. Brueckmann, N. D. Gollop, T. Iwata, P. Ponikowski, C. Wanner, F. Zannad, M. Packer, S. D. Anker

Research output: Contribution to journal › Abstract › peer-review

Original language	English
Pages (from-to)	131-132
Number of pages	2
Journal	European Journal of Heart Failure
Volume	24
Issue number	S2
DOIs	https://doi.org/10.1002/ejhf.2569
Publication status	Published - 1 Jul 2022
Externally published	Yes

Access to Document

10.1002/ejhf.2569

Cite this

Boehm, M., Butler, J., Filippatos, G., Ferreira, J. P., Pocock, S. J., Abdin, A., Mahfoud, F., Brueckmann, M., Gollop, N. D., Iwata, T., Ponikowski, P., Wanner, C., Zannad, F., Packer, M., & Anker, S. D. (2022). Empagliflozin improves cardiovascular and renal outcomes in patients with preserved ejection fraction irrespective of age: insights from the EMPEROR-Preserved trial. European Journal of Heart Failure, 24(S2), 131-132. https://doi.org/10.1002/ejhf.2569

@article{26fb0f2c0d1840b29ee6717c51587e78,

title = "Empagliflozin improves cardiovascular and renal outcomes in patients with preserved ejection fraction irrespective of age: insights from the EMPEROR-Preserved trial",

author = "Michael Boehm and J. Butler and G. Filippatos and Ferreira, {J. P.} and Pocock, {S. J.} and A. Abdin and F. Mahfoud and M. Brueckmann and Gollop, {N. D.} and T. Iwata and P. Ponikowski and C. Wanner and F. Zannad and M. Packer and Anker, {S. D.}",

year = "2022",

month = jul,

day = "1",

doi = "10.1002/ejhf.2569",

language = "English",

volume = "24",

pages = "131--132",

journal = "European Journal of Heart Failure",

issn = "1388-9842",

publisher = "Wiley",

number = "S2",

}

Boehm, M, Butler, J, Filippatos, G, Ferreira, JP, Pocock, SJ, Abdin, A, Mahfoud, F, Brueckmann, M, Gollop, ND, Iwata, T, Ponikowski, P, Wanner, C, Zannad, F, Packer, M & Anker, SD 2022, 'Empagliflozin improves cardiovascular and renal outcomes in patients with preserved ejection fraction irrespective of age: insights from the EMPEROR-Preserved trial', European Journal of Heart Failure, vol. 24, no. S2, pp. 131-132. https://doi.org/10.1002/ejhf.2569

TY - JOUR

T1 - Empagliflozin improves cardiovascular and renal outcomes in patients with preserved ejection fraction irrespective of age

T2 - insights from the EMPEROR-Preserved trial

AU - Boehm, Michael

AU - Butler, J.

AU - Filippatos, G.

AU - Ferreira, J. P.

AU - Pocock, S. J.

AU - Abdin, A.

AU - Mahfoud, F.

AU - Brueckmann, M.

AU - Gollop, N. D.

AU - Iwata, T.

AU - Ponikowski, P.

AU - Wanner, C.

AU - Zannad, F.

AU - Packer, M.

AU - Anker, S. D.

PY - 2022/7/1

Y1 - 2022/7/1

U2 - 10.1002/ejhf.2569

DO - 10.1002/ejhf.2569

M3 - Abstract

VL - 24

SP - 131

EP - 132

JO - European Journal of Heart Failure

JF - European Journal of Heart Failure

SN - 1388-9842

IS - S2

ER -